Indiana is banking $6.25 million after Attorney General Todd Rokita cut a deal with pharmaceutical companies accused of rigging the market on EpiPen. The settlement, announced yesterday, wraps up a case the state launched in January 2025 over what it called a yearslong effort to keep prices for the life-saving allergy injector artificially high and Hoosiers stuck with the tab.
Settlement and case basics
Rokita’s office said the $6.25 million payment will go to the state as part of a settlement with Viatris, Pfizer and related subsidiaries, according to The Indiana Lawyer. Indiana’s complaint accused the companies of violating three key statutes: the Indiana Antitrust Act, the Indiana Deceptive Consumer Sales Act and the Medicaid False Claims Act. The case started in Marion County Superior Court before being transferred to the U.S. District Court for the Southern District of Indiana.
Alleged tactics at issue
The state’s lawsuit laid out a playbook of alleged tactics that, it said, kept cheaper competition on the sidelines and EpiPen prices climbing, as reported by WDRB. Indiana claimed the companies repeatedly raised EpiPen’s list price, paid pharmacy benefit managers to exclude rival products, and promoted two-pack EpiPen prescriptions while cutting back on single-unit sales. According to the complaint, those moves, paired with efforts to get doctors to endorse the medical necessity of two-packs, helped cement EpiPen’s market dominance. The state alleged that from 2007 to 2016 the list price jumped more than 600 percent, which it says led Medicaid and other payors to be overcharged.
Where this fits in a bigger fight
Indiana’s case is one piece of a larger legal barrage over EpiPen pricing and sales tactics. Across the country, class actions and multistate lawsuits have already delivered settlements to direct buyers and government entities, according to a notice from Business Wire. Long-running coverage has documented how EpiPen’s list price moved from under $100 to roughly $600 for a two-pack during the 2000s and 2010s, putting the injector at the center of national outrage and congressional hearings, as detailed by The Washington Post. Compared with some of the massive nationwide payouts, Indiana’s recovery is modest, but it adds another brick in the wall of state-level pressure on drug pricing practices.
Companies' response
The settlement resolves Indiana’s claims against Viatris, Pfizer and their subsidiaries, and the companies denied any wrongdoing as part of the deal, according to WISH‑TV. The Indiana Lawyer reported that attorneys for the defendants did not immediately respond to requests for comment. It also remains unclear whether the agreement includes any injunctions or other non monetary terms that would change how EpiPen is marketed or reimbursed going forward.
What’s next
Because the companies explicitly denied liability, the settlement closes Indiana’s case without any admission of guilt. Any further fallout will depend on subsequent court filings and on whether other plaintiffs continue to pursue related claims, according to a release from the State of Indiana. The state has not yet explained how it plans to allocate the $6.25 million. Future filings or statements from plaintiffs’ counsel could clarify whether insurers, government programs or individual consumers might see any direct payments. Rokita, who has taken on multiple drug-pricing cases in recent years, has said the outcome should send a warning shot to companies considering similar tactics.
Legal implications
Indiana’s complaint cited the Indiana Antitrust Act, the Indiana Deceptive Consumer Sales Act and the Medicaid False Claims Act, laws that can bring civil penalties, restitution and injunctive relief if a court finds violations, according to WDRB. As is common in civil settlements of this kind, the agreement includes a no admission provision, so the underlying allegations have not been tested at trial. If related federal litigation continues, judges and appellate courts could still shape how liability and remedies for EpiPen pricing are defined across different states.
